XML 68 R37.htm IDEA: XBRL DOCUMENT v3.22.4
Identifiable Intangible Assets and Goodwill (Tables)
 12 Months Ended
Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Finite-Lived Intangible Assets
The following summarizes the components of Identifiable intangible assets:
 As of December 31, 2022As of December 31, 2021
(MILLIONS)Gross
Carrying
Amount		Accumulated
Amortization		Identifiable
Intangible
Assets, less
Accumulated
Amortization		Gross
Carrying
Amount		Accumulated
Amortization		Identifiable
Intangible
Assets, less
Accumulated
Amortization
Finite-lived intangible assets
Developed technology rights(a)
$85,604 $(56,307)$29,297 $73,346 $(53,732)$19,614 
Brands922 (844)78 922 (807)115 
Licensing agreements and other2,237 (1,397)841 2,284 (1,299)985 
88,763 (58,548)30,215 76,552 (55,838)20,714 
Indefinite-lived intangible assets
Brands827 827 827 827 
IPR&D(b)
11,357 11,357 3,092 3,092 
Licensing agreements and other(b)
971 971 513 513 
13,155 13,155 4,432 4,432 
Identifiable intangible assets(c)
$101,919 $(58,548)$43,370 $80,984 $(55,838)$25,146 
(a)The increase in the gross carrying amounts mainly reflect the impact of the acquisitions of Biohaven and GBT (see Note 2A).
(b)The increase in the gross carrying amounts mainly reflect the impact of the acquisitions of Arena, GBT and Biohaven (see Note 2A), and for IPR&D, is partially offset by an impairment (see Note 4).
(c)The increase is primarily due to acquisitions (see Note 2A), partially offset by amortization expense.
Schedule of Indefinite-Lived Intangible Assets
The following summarizes the components of Identifiable intangible assets:
 As of December 31, 2022As of December 31, 2021
(MILLIONS)Gross
Carrying
Amount		Accumulated
Amortization		Identifiable
Intangible
Assets, less
Accumulated
Amortization		Gross
Carrying
Amount		Accumulated
Amortization		Identifiable
Intangible
Assets, less
Accumulated
Amortization
Finite-lived intangible assets
Developed technology rights(a)
$85,604 $(56,307)$29,297 $73,346 $(53,732)$19,614 
Brands922 (844)78 922 (807)115 
Licensing agreements and other2,237 (1,397)841 2,284 (1,299)985 
88,763 (58,548)30,215 76,552 (55,838)20,714 
Indefinite-lived intangible assets
Brands827 827 827 827 
IPR&D(b)
11,357 11,357 3,092 3,092 
Licensing agreements and other(b)
971 971 513 513 
13,155 13,155 4,432 4,432 
Identifiable intangible assets(c)
$101,919 $(58,548)$43,370 $80,984 $(55,838)$25,146 
(a)The increase in the gross carrying amounts mainly reflect the impact of the acquisitions of Biohaven and GBT (see Note 2A).
(b)The increase in the gross carrying amounts mainly reflect the impact of the acquisitions of Arena, GBT and Biohaven (see Note 2A), and for IPR&D, is partially offset by an impairment (see Note 4).
(c)The increase is primarily due to acquisitions (see Note 2A), partially offset by amortization expense.
Schedule of Expected Amortization Expense
The following provides the expected annual amortization expense:
(MILLIONS)20232024202520262027
Amortization expense$4,223 $3,981 $3,780 $3,714 $3,503 
Schedule of Goodwill
The following summarizes the changes in the carrying amount of Goodwill:
(MILLIONS)
Total(a)
Balance, January 1, 2021
$49,556 
Additions— 
Impact of foreign exchange(348)
Balance, December 31, 2021
49,208 
Additions(b)
2,917 
Impact of foreign exchange(750)
Balance, December 31, 2022
$51,375 
(a)As a result of the organizational changes to the commercial structure within the Biopharma operating segment effective in the third quarter of 2022 (see Note 1A), our goodwill was required to be reallocated amongst impacted reporting units. The allocation of goodwill is a complex process that requires, among other things, that we determine the fair value of each reporting unit under our old and new organizational structure and the portions being transferred. We completed this re-allocation during the fourth quarter 2022 and concluded that none of our goodwill was impaired. Our goodwill balance continues to be assigned within the Biopharma reportable segment.
(b)Additions relate to our acquisitions of GBT, Arena and Biohaven. See Note 2A.